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Abstract
It has been suggested that taurine chloramine (TauCl) plays an
important role in the downregulation of proinflammatory
mediators. However, little is known about its effect on the
expression of matrix metalloproteinases (MMPs). In this study,
we investigated the effects of TauCl on synovial expression of
MMPs. The effects of TauCl on MMP expression in IL-1β
stimulated fibroblast-like synoviocytes (FLSs) were studied
using the following techniques. Real-time PCR and semi-
quantitative PCR were employed to analyze the mRNA
expression of MMPs. ELISA was used to determine protein
levels of MMPs. Western blot analyses were performed to
analyze the mitogen-activated protein kinase and inhibitor of
nuclear factor-κB (IκB) kinase signalling pathways. Finally,
electrophoretic mobility shift assay and immunohistochemistry
were used to assess localization of transcription factors. IL-1β
increased the transcriptional and translational levels of MMP-1
and MMP-13 in rheumatoid arthritis FLSs, whereas the levels of
MMP-2 and MMP-9 were unaffected. TauCl at a concentration
of 400 to 600 μmol/l greatly inhibited the transcriptional and
translational expression of MMP-13, but the expression of MMP-
1 was significantly inhibited at 800 μmol/l. At a concentration of
600 μmol/l, TauCl did not significantly inhibit phosphorylation of
mitogen-activated protein kinase or IκB degradation in IL-1β
stimulated rheumatoid arthritis FLSs. The degradation of IκB
was significantly inhibited at a TauCl concentration of 800 μmol/
l. The inhibitory effect of TauCl on IκB degradation was
confirmed by electrophoretic mobility shift assay and
immunochemical staining for localization of nuclear factor-κB.
TauCl differentially inhibits the expression of MMP-1 and MMP-
13, and inhibits expression of MMP-1 primarily through the
inhibition of IκB degradation, whereas it inhibits expression of
MMP-13 through signalling pathways other than the IκB
pathway.
Introduction
The characteristics of rheumatoid arthritis (RA) include
chronic proliferative synovitis, infiltration of inflammatory
immune cell types into the synovial fluid of joints, and cartilage
destruction. Proliferative fibroblast-like synoviocytes (FLSs)
play crucial roles in both joint damage and propagation of
inflammation because they produce many mediators of inflam-
mation and matrix metalloproteinases (MMPs), which
ELISA = enzyme-linked immunosorbent assay; EMSA = electrophoretic mobility shift assay; ERK = extracellular signal-regulated kinase; FLS = fibrob-
last-like synoviocyte; HOCl = hypochlorous acid; IκB = inhibitor of nuclear factor-κB; IL = interleukin; JNK = c-jun amino-terminal kinase; MAPK = 
mitogen-activated protein kinase; MMP = matrix metalloproteinase; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF-κB = 
nuclear factor-κB; PBS = phosphate-buffered saline; PCR = polymerase chain reaction; PMSF = phenylmethylsuphonyl fluoride; RA = rheumatoid 
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contribute to cartilage degradation in joints [1]. Immune cells
recruited into joint cavities by FLSs also contribute to progres-
sive destruction of cartilage in distal joints [2]. Among the
range of detrimental immune cells that are present in RA joints,
neutrophils have been a primary focus of research in RA
because of their number and function [3-7]. Once activated,
neutrophils secrete various mediators, including MMPs and, in
particular, the reactive oxygen intermediates nitric oxide and
hypochlorous acid (HOCl) [8,9]. Thus, neutrophils play an
important role in the pathogenesis of RA [9].
However, neutrophils also appear to possess homeostatic
mechanisms that can reduce the inflammatory response. Acti-
vated neutrophils contain substantial quantities of taurine,
which is one of the most abundant free intracellular amino
acids present in mammalian tissues and blood cells [10,11].
Taurine acts as a scavenger of HOCl, which is produced by
the myeloperoxidase/hydrogen peroxide/chloride system of
activated neutrophils and monocytes [12]. It reacts with HOCl
to form taurine chloramine (TauCl). Notably, TauCl has been
shown to play a major role in downregulating the expression of
inflammatory mediators such as chemokines, cytokines, cyclo-
oxygenase-2 and inducible nitric oxide synthase in various
types of cells [13-18]. Such inhibitory effects have also been
demonstrated in animal models of arthritis [19,20]. These
inhibitory effects may stem from the suppressive effects of
TauCl on expression of proinflammatory mediators (prostag-
landin E2, nitric oxide, and cytokines) and bone erosion related
enzymes, such as MMPs.
MMPs, which are primarily produced in fibroblast-like synovio-
cytes (FLSs) in RA, are proteases that participate in irrepara-
ble proteolytic degradation and in the remodelling of the
extracellular matrix. MMPs can be classified into five main
groups, according to their substrate specificities, primary
structures and cellular localizations [21]: collagenases (MMP-
1, MMP-8 and MMP-13), gelatinases (MMP-2 and MMP-9),
stromelysins (MMP-3 and MMP-10), matrilysins (MMP-7 and
MMP-26) and membrane-bound membrane-type MMPs
(MMP-14, MMP-15, MMP-16, MMP-17, MMP-24 and MMP-
25). The MMP-1 and MMP-13 collagenases play dominant
roles in RA and osteoarthritis because they are rate-limiting
components of the collagen degradation process [22,23]. In
particular, MMP-13 is a potent protease that is capable of
degrading a wide range of collagenous and noncollagenous
extracellular matrix macromolecules [24,25]. MMP-13 is
remarkably active against collagen type II, which is the pre-
dominant collagen in cartilage [26]. To date, investigations of
TauCl have focused on its inhibitory effects on the expression
of proinflammatory mediators. However, despite the important
roles played by MMPs in cartilage erosion, the effects of TauCl
on expression of MMPs are not well understood. In this report
we show that TauCl inhibits the increased expression of the
MMP-1 and MMP-13 genes in IL-1β stimulated RA FLSs.
Materials and methods
Primary culture of fibroblast-like synoviocytes
After obtaining informed consent, synovial tissues were col-
lected from RA patients who met the 1987 American College
of Rheumatology criteria for the diagnosis of RA and who were
undergoing therapeutic joint surgery. FLSs were isolated as
follows. Tissues were digested with gentle shaking in 20 ml
RPMI 1640 (Gibco-BRL, Grand Island, NY, USA) containing
1 mg/ml collagenase (Gibco-BRL) at 37°C for 90 min, filtered
through a 70 μm cell strainer and cultured in 75 cm2 culture
flasks with Dulbecco's modified essential medium (Gibco-
BRL) supplemented with 20% (vol/vol) foetal bovine serum
(Gibco-BRL) and 1× antibiotic-antimycotic (Gibco-BRL). After
the cells had grown to confluence, they were detached with
0.25% trypsin (Gibco-BRL) and split at a 1:4 ratio. FLS pas-
sages three to six were used for all experiments. Visual exami-
nation of cell morphology under light microscopy and
fluorescence activated cell sorting analysis of cells stained
with anti-CD11b antibody (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) confirmed that FLSs accounted for more than
95% of the cells.
Preparation of TauCl
TauCl was synthesized by mixing equimolar amounts of
sodium hypochlorite (Aldrich Chemical, Milwaukee, MI, USA)
and taurine (Sigma, St. Louis, MO, USA). TauCl formation was
verified by UV absorption (200 to 400 nM) [27]. Endotoxin-
free or low-endotoxin grade water and buffers were used.
Stock solutions of taurine and TauCl were kept at 4°C and
used within 3 days.
Semi-quantitative RT-PCR
TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) was used to
extract total RNA from arthritic FLSs (2.5 × 105 cells/60-mm
dish/2 ml serum-free media) that had been starved in serum-
free media overnight and treated with IL-1β for 6 hours in the
presence or absence of TauCl. Complementary DNA was syn-
thesized from 1 μg total RNA in 20 μl reverse transcription
reaction mixture containing 5 mmol/l MgCl2, 1× RT buffer, 1
mmol/l dNTP, 1 U/μl RNase inhibitor, 0.25 U/μl AMV reverse
transcriptase, and 2.5 μmol/l random 9-mers. For semi-quanti-
tative PCR, aliquots of cDNA were amplified with the primers
in a 25 μl PCR mixture containing 1× PCR buffer, 0.625 units
of TaKaRa Ex Taq™ HS, and 0.2 μmol/l of specific upstream
primers, in accordance with the manufacturer's protocol
(TaKaRa Bio, Kyoto, Japan). The PCR conditions for the
MMPs were as follows: 30 to 33 cycles at 95°C for 45 s, 55
to 60°C for 45 s, and 72°C for 45 s. PCR products were sub-
jected to electrophoresis in 1.5% agarose gels containing
ethidium bromide, and the bands were visualized under UV
light. The primers were synthesized by Bioneer Co. Ltd (Seoul,
Republic of Korea), and their sequences are listed in Table 1.Available online http://arthritis-research.com/content/9/4/R80
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Real-time PCR
For real-time quantitative PCR analysis, the reaction was car-
ried out using the LightCycler PCR system (Roche Diagnos-
tics, Meylan, France), with the DNA-binding SYBR Green I dye
used to detect the PCR products. A serial dilution was used
to generate each standard curve. Each 20 μl reaction mixture
contained 1× LightCycler-DNA Master SYBR Green I, a spe-
cific primer, along with 2 μl cDNA. After 2 min denaturation at
95°C, the MMPs and β-actin underwent 40 reaction cycles at
95°C for 5 s, 55 to 60°C for 10 s (annealing) and 72°C for 13
s. Product specificity was determined by melting curve analy-
sis, as described in the LightCycler manual. The results are
expressed as ratios of MMP transcripts to β-actin transcripts,
with the quantity of transcripts in each sample expressed as a
copy number. The ratio of MMP/β-actin mRNA was assigned
a value of 100%, with the corresponding results calculated as
relative percentages.
Enzyme-linked immunosorbent assay
The levels of MMP-1 and MMP-13 secreted in the culture
media by IL-1β stimulated FLSs (5 × 105 cells/60-mm dish/2-
ml serum-free media) in the presence or absence of TauCl
were measured by ELISA (R&D Systems, Inc., Minneapolis,
MN, USA).
Western blot analysis
FLSs (5 × 105 cells) cultured in 60-mm dishes were serum
starved overnight and stimulated by IL-1β (10 ng/ml) for 10 or
30 min in the presence or absence of TauCl. The cells were
subsequently washed twice in phosphate-buffered saline
(PBS) and treated with 50 μl lysis buffer (20 mmol/l Tris-Cl
[pH 8.0], 150 mmol/l NaCl, 1 mmol/l EDTA, 1% Triton X-100,
20 μg/ml chymostatin, 2 mmol/l phenylmethylsuphonyl fluo-
ride [PMSF], 10 μmol/l leupeptin, and 1 mmol/l 4-[2-aminoe-
thyl]benzenesulfonyl fluoride). Cells were scraped using a
rubber policeman before addition of another 50 μl lysis buffer.
The cells were transferred to a microcentrifuge tube, incu-
bated on ice for 30 min with occasional agitation every 5 min
and centrifuged for 15 min at 12,000 rpm (16,090 g), and the
supernatant was then analyzed for protein concentration using
the Bio-Rad Protein Assay Kit (Bio-Rad, Hercules, CA, USA).
Thirty micrograms of cytoplasmic protein extract were then
boiled in 5× Laemmli sample buffer for 5 min. The samples
were separated by 12% SDS-PAGE and transferred to a
Hybond-ECL membrane (Amersham, Arlington Heights, IL,
USA). The membranes were blocked with 6% nonfat milk dis-
solved in TBST buffer (10 mmol/l Tris-Cl [pH 8.0], 150 mmol/
l NaCl, 0.05% Tween 20). The blots were probed with various
rabbit polyclonal antibodies for phosphorylated extracellular
signal regulated kinase-1/2 (phospho-ERK-1/2), phosphar-
ylated p38 (phospho-p38), phospharylated c-jun amino-termi-
nal kinase (phospho-JNK), and inhibitor of nuclear factor-κB
(IκB)α (Cell Signaling Technology, Beverly, MA, USA) diluted
1:1000 in Tris-buffered saline for 2 hours and incubated with
1:1000 dilutions of goat anti-rabbit IgG secondary antibody,
coupled with horseradish peroxidase. The blots were devel-
oped using the ECL method (Amersham). For re-probing, the
blots were incubated in the stripping buffer (100 mmol/l 2-
mercaptoethanol, 2% SDS, 62.5 mmol/l Tris-HCl [pH 6.7]) at
50°C for 30 min with occasional agitation.
Preparation of nuclear extracts
FLSs (2 × 106 cells) were seeded in 100-mm dishes and cul-
tured for 2 days. The cells were kept in serum-free medium
overnight and pretreated with TauCl 30 min before IL-1β (10
ng/ml) stimulation for 90 min. The cells were then washed with
cold PBS, and nuclear extracts were prepared by cell lysis
followed by nuclear lysis. In brief, cells were suspended in 400
μl of buffer A (10 mmol/l HEPES [pH 7.9], 1.5 mmol/l MgCl2,
10 mmol/l KCl, 0.5 mmol/l DTT, 1 μmol/l leupeptin and 0.2
mmol/l PMSF) and vortexed for 15 s. After incubation for 20
min at 4°C, the lysates were centrifuged at 10,000 g for 6 min.
Table 1
The sequence of PCR primers used in this experiment
Primer name Primer sequence Product size
MMP-1 sense 5'-CCT AGC TAC ACC TTC AGT GG-3' 338 bp
MMP-1 antisense 5'-GCC CAG TAC TTA TTC CCT TT-3'
MMP-13 sense 5'-TTG AGG ATA CAG GCA AGA CT-3' 311 bp
MMP-13 antisense 5'-TGG AAG TAT TAC CCC AAA TG-3'
MMP-2 sense 5'-ACT TCA GGC TCT TCT CCT TT-3' 288 bp
MMP-2 antisense 5'-TTC AGA CAA CCT GAG TCC TT-3'
MMP-9 sense 5'-TAC CCT ATG TAC CGC TTC AC-3' 345 bp
MMP-9 antisense 5'-GAA CAA ATA CAG CTG GTT CC-3'
β-actin sense 5'-TCA TGA GGT AGT CAG TCA GG-3' 305 bp
β-actin antisense 5'-CTT CTA CAA TGA GCT GCG TG-3'
bp, base pairs; MMP, matrix metalloproteinase.Arthritis Research & Therapy    Vol 9 No 4    Kim et al.
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The unclear pellet was re-suspended in buffer B (20 mmol/l
HEPES [pH 7.9], 25% glycerol, 420 mmol/l NaCl, 1.5 mmol/l
MgCl2, 0.2 mmol/l EDTA, 0.5 mmol/l DTT, 1 μmol/l leupeptin
and 0.2 mmol/l PMSF), incubated on ice for 40 min and cen-
trifuged at 10,000 g for 20 min. Protein concentrations were
determined using the Bradford method (Bio-Rad).
Electrophoretic mobility shift assay
The protein-DNA binding activity in nuclear factor-κB (NF-κB)
was determined using electrophoretic mobility shift assay
(EMSA). In brief, 10 μg nuclear protein was incubated with
0.25  μg of poly(dI-dC) (Amersham) and 32P-labelled DNA
probe (5,000 counts per minute) in binding buffer (10 mmol/l
Tris-HCl [pH 7.5], 50 mmol/l NaCl, 1 mmol/l MgCl2, 0.5 mmol/
l EDTA, 5% glycerol and 0.5 mmol/l DTT) for 30 min at 30°C.
The protein-DNA complexes were then analyzed on 5% native
polyacrylamide gels. For the supershift experiment, antibodies
were included in the above reaction mixture and incubated at
4°C for 3 hours before the addition of the 32P-labelled DNA
probe. The oligonucleotide sequences used to detect NF-κB
activity were as follows: 5'-AGT TGA GGG GAC TTT CCC
AGG-3' (sense) and 5'-GCC TGG GAA AGT CCC CTC AAC
T-3' (antisense).
Immunofluorescence staining
FLSs were cultured at 4 × 104 cells/well in four-well Lab-Tek
chamber slides (Falcon; Becton Dickinson Labware, Oxnard,
CA, USA) in order to visualize the translocation of NF-κB to
the nucleus under IL-1β stimulation. After serum starvation
overnight, the cells were stimulated with IL-1β at 10 ng/ml for
90 min, washed with cold PBS, and fixed with 4% paraformal-
dehyde in PBS for 20 min. Cells were permeabilized with PBS
and 0.5% Triton X-100 in PBS for 10 min, and were then incu-
bated for 30 min with the blocking buffer, 5% goat serum, in
order to prevent nonspecific binding. The cells were incubated
with 5 μg/ml rabbit polyclonal anti-NF-κB p65 antibody (Santa
Cruz Biotechnology) overnight, followed by incubation with 20
μg/ml cyan3-conjugated goat anti-rabbit antibody for 60 min
at room temperature. After washing, the cells were counter-
stained with 0.1 mg/ml DAPI for 30 min at room temperature.
The coverslips were fixed with mounting media (DakoCytoma-
tion, Carpinteria, CA, USA), and the slides were visualized
using confocal microscopy (Carl Zeiss, Oberkochen,
Germany).
In vitro cytotoxicity
TauCl cytotoxicity was assessed by a colorimetric assay using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT). In brief, FLSs (2.5 × 105 cells/2 ml) were seeded into
six-well plates. After overnight incubation at 37°C, the medium
was replaced with serum-free medium and treated with TauCl
30 min before stimulation with IL-1β (10 ng/ml). Cells were
subsequently cultured for 24 hours, and MTT solution (5 mg/
ml) was added to each well at a final concentration of 0.5 mg/
ml. The plates were incubated for 4 hours at 37°C, and forma-
zan crystals were dissolved by the addition of 1 ml isopropanol
containing 0.04 M HCl. Finally, absorbance was measured at
595 nm.
Statistical analysis
All experiments were repeated three times, and the results are
expressed as the mean ± standard deviation. Statistical evalu-
ation was performed by means of a paired Student's t-test. Dif-
ferences were considered statistically significant at P < 0.05.
Results
TauCl differentially inhibits the expression of MMP-1 
and MMP-13
The stimulation of arthritic FLSs using IL-1β greatly upregu-
lated the expressions of the MMP-1 and MMP-13 colla-
genases, as determined by ELISA (Figure 1a), real time PCR
(Figure 1b) and semi-quantitative RNA analysis (Figure 1c).
However, the expressions of the gelatinases MMP-2 and
MMP-9 remained unchanged (Figure 1). MMP-2 and MMP-9
remained unchanged at the mRNA level, even after 24 hours
of stimulation, which indicates that IL-1β did not stimulate
MMP-2 and MMP-9 (data not shown). Consistent with the
mRNA levels of MMP-1 and MMP-13, ELISA analyses of cul-
ture supernatants at 24 hours revealed that IL-1β upregulated
the expressions of MMP-1 and MMP-13 at the protein level by
about 30-fold and 15-fold, respectively (Figure 1a). The pro-
tein levels of the MMP-2 remained unchanged, whereas the
protein levels of the MMP-9 genes were below the ELISA
detection limit (data not shown).
To identify whether TauCl inhibits the expression of MMPs,
FLSs were treated with TauCl 30 min before 24 hours or 6
hours of IL-1β stimulation for protein analysis and RNA analy-
sis, respectively. Treatment with TauCl at concentrations of
400 and 600 μmol/l differentially inhibited the expressions of
MMP-1 and MMP-13. The expression of MMP-1 remained
unchanged at TauCl 400 and 600 μmol/l, whereas MMP-13
levels were reduced to about 50% or 20% of that observed in
the IL-1β treated group (with no TauCl treatment), respectively
(Figure 1a). However, at a TauCl concentration of 800 μmol/l,
the protein expressions of MMP-1 and MMP-13 diminished to
50% and 10%, respectively.
Consistent with the effects of TauCl on the protein levels of
MMP-1 and MMP-13, RNA analyses revealed that the levels of
MMP-13 were more sensitive to TauCl at a concentration of
600 μmol/l than were the levels of MMP-1. At a TauCl concen-
tration of 800 μmol/l, the transcriptional expressions of the
MMP-1 and MMP-13 genes diminished to 20% and 5%,
respectively (Figure 1b,c).
IL-1β stimulates the signalling pathways of both MAPK 
and IκB kinase
IL-1β stimulates the signal transduction pathways of both
mitogen-activated protein kinase (MAPK) and IκB kinase inAvailable online http://arthritis-research.com/content/9/4/R80
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chondrocytes and astrocytes [28,29]. To identify the path-
ways that are involved in enhancing MMP-1 and MMP-13
expression under IL-1β stimulation, the levels of phospho-
ERK-1/2, phospho-JNK, phospho-p38MAPK and IκBα were
measured according to the duration of stimulation. IL-1β treat-
ment led to remarkable increases in the phosphorylation of
ERK-1/2 and p38MAPK by 10 min, and the increased levels
were maintained for 45 min. The level of phospho-JNK peaked
at 30 min. IκBα was completely degraded at 30 min but recov-
ered by 60 min, which indicates that IκBα was fully phospho-
rylated within 30 min of activation of IL-1β (Figure 2a).
TauCl primarily inhibits the IκBα pathway
We investigated the level of MAPK phosphorylation in an effort
to clarify the inhibitory mechanism of TauCl on MMPs. As
shown in Figure 2b, TauCl did not significantly inhibit the phos-
phorylation of ERK-1/2, p38, or JNK, even when the highest
test concentration of 800 μmol/l was used. At 800 μmol/l,
TauCl strongly blocked the IκB degradation that normally
occurs upon IL-1β stimulation, which suggests that TauCl pre-
vents NF-κB from migrating to the nucleus by inhibiting the
degradation of IκB. The effectiveness of TauCl as an inhibitor
of IκB was investigated by comparing it with MG132, which is
an NF-κB inhibitor that slows IκB degradation by deactivating
Figure 1
TauCl differentially inhibits the expression of MMPs in IL-β-stimulated RA FLSs TauCl differentially inhibits the expression of MMPs in IL-β-stimulated RA FLSs. The expressions of the collagenases (matrix metalloproteinase 
[MMP]-1 and MMP-13) and the gelatinases (MMP-2 and MMP-9) were determined by (a) ELISA analysis, (b) real time PCR and (c) semi-quantita-
tive RNA analysis. Synovial cells (5 × 105 cells/60 mm dish/2 ml serum-free media) were treated with taurine chloramine (TauCl) 30 min before 24 
hours of IL-1β (10 ng/ml) stimulation for MMP protein analysis by ELISA. Cells (2.5 × 105 cells/60 mm dish/2 ml serum-free media) were treated 
with TauCl 30 min before 6 hours of stimulation with IL-1β (10 ng/ml) for RNA level analysis. IL-1β stimulated the expression of the MMP-1 and 
MMP-13 genes, but it did not affect the expression of MMP-2 or MMP-9. TauCl differentially inhibited the expressions of MMP-1 and MMP-13. 
Experiments were performed in duplicate with cells from three patients. Values are expressed as means ± standard deviation. *P < 0.01 versus con-
trol group (no IL-1β); #P < 0.05 and ##P < 0.01 versus IL-1β treatment group without TauCl. FLS, fibroblast-like synoviocyte; PBS, phosphate-buff-
ered saline; RA, rheumatoid arthritis.Arthritis Research & Therapy    Vol 9 No 4    Kim et al.
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the proteasome [30]. TauCl inhibited IκB degradation as
potently as MG132, in this instance; however, the concentra-
tion of TauCl employed was greater than that of MG132 (Fig-
ure 3).
TauCl blocks NF-κB nuclear translocation through the 
inhibition of IκB degradation
To further demonstrate that the effects of IκB degradation
extended to the transnuclear migration of NF-κB, levels of NF-
κB in the nucleus were assessed using EMSA (Figure 4) and
immunohistochemistry (Figure 5). As shown in Figure 4, at a
concentration of 800 μmol/l, TauCl completely blocked the
nuclear binding of NF-κB; however, at 600 αmol/l, TauCl did
not block binding activity. These results were confirmed by
confocal microscopy. After 90 min of IL-1β stimulation, the
majority of cytoplasmic NF-κB migrated into the nucleus, as
indicated by strong nuclear NF-κB staining following stimula-
tion and strong cytoplasmic staining before stimulation (Figure
5). Confirming previous findings, the migration of NF-κB into
the nucleus was not inhibited at TauCl concentrations of up to
600 μmol/l. However, at a concentration of 800 μmol/l, TauCl
blocked the transnuclear migration of NF-κB.
Figure 2
TauCl primarily inhibited the degradation of IκB TauCl primarily inhibited the degradation of IκB. (a) Synovial cells (5 × 105 cells/60 mm dish/2 ml serum-free media) were treated with IL-1β (10 ng/
ml). Shown are time courses of the signalling pathways activated during IL-1β stimulation. (b) Synovial cells (5 × 105 cells/60 mm dish/2 ml serum-
free media) were treated with taurine chloramine (TauCl) 30 min before 10 or 30 min of IL-1β (10 ng/ml) stimulation for Western blot analysis. A 
TauCl concentration of 800 μmol/l significantly inhibited the inhibitor of nuclear factor-κB (IκB)/nuclear factor-κB (NF-κB) signalling pathway by 
inhibiting the degradation of IκBα. The mitogen-activated protein kinase (MAPK) signalling pathway, including extracellular signal-regulated kinase 
(ERK)-1/2, p38 and c-jun amino-terminal kinase (JNK), was unaffected. Three independent experiments were performed with cells from two patients. 
p, phosphorylated.
Figure 3
TauCl inhibited IκBα degradation as potently as did a NF-κB inhibitor  (MG132) TauCl inhibited IκBα degradation as potently as did a NF-κB inhibitor 
(MG132). Synovial cells (5 × 105 cells/60 mm dish/2 ml serum-free 
media) were treated with taurine chloramine (TauCl) or MG132 30 min 
before IL-1β (10 ng/ml) stimulation for 30 min. At a concentration of 
800 μmol/l, TauCl inhibited the degradation of inhibitor of nuclear fac-
tor-κB (IκB)α just as potently as did 1 μmol/l MG132. Three independ-
ent experiments were performed with cells from two patients. NF-κB, 
nuclear factor-κB.
Figure 4
TauCl inhibited NF-κB binding activity TauCl inhibited NF-κB binding activity. Synovial cells (2 × 106 cells/
100-mm dish/5-ml serum-free media) were pretreated with taurine 
chloramine (TauCl) or taurine (Tau) 30 min prior to IL-1β stimulation for 
90 min. Nuclear extracts were prepared for electrophoretic mobility 
shift assay (EMSA). IL-1β stimulation increased nuclear levels of 
nuclear factor-κB (NF-κB). At a concentration of 800 μmol/l, TauCl 
completely inhibited NF-κB binding. Antibodies against the p65 subunit 
of NF-κB induced a gel shift in the NF-κB band. Three independent 
experiments were performed with cells from two patients.Available online http://arthritis-research.com/content/9/4/R80
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Discussion
Because IL-1β is believed to play a major role in synovial
inflammation, RA FLSs stimulated with IL-1β in vitro have been
used to mimic the synovial proliferation that occurs in RA
patients suffering from inflammation [31]. IL-1β is also known
to stimulate many proinflammatory mediators in a variety of cell
types [32]. In addition, IL-1β is a potent inducer of
metalloproteinase production by FLSs; however, little investi-
gation has been conducted to determine its effects on the
gelatinases (MMP-2 and MMP-9) [33]. In the present study,
we found that IL-1β strongly stimulated the expression of col-
lagenases (MMP-1 and MMP-13). Gelatinase expression was
weakly activated by IL-1β stimulation. However, IL-1β is known
to induce high levels of gelatinase expression in other cell
types [34-36].
IL-1β activates different signalling pathways in different cell
types. Thus, we investigated signalling pathways in IL-1β stim-
ulated RA FLSs [37]. IL-1β stimulated the pathways of both
MAPK (ERK, p38 and JNK) and IκB kinase within 30 min, with
pathway activation subsiding to the basal levels of nonstimu-
lated cells by 60 min. The activation of these pathways led to
the activation of a number of transcriptional factors that
enhance the expression of various proinflammatory mediators.
Among these factors, NF-κB is a key regulator of inflammatory
gene transcription, and it is known to be activated in RA syno-
via and chondrocytes [38].
TauCl differentially inhibited the expression of MMPs in IL-1β
stimulated RA FLSs. The expression of MMP-13 was
significantly inhibited at concentrations of 400 to 600 μmol/l
TauCl, whereas the expression of MMP-1 was not significantly
inhibited at this concentration. To clarify the inhibitory mecha-
nism of TauCl on MMPs, the levels of both MAPK phosphor-
ylation and IκB degradation were investigated in IL-1β
stimulated RA FLSs. TauCl did not significantly inhibit the
phosphorylation of ERK-1/2, p38, or JNK, even at 800 μmol/l,
whereas IκB degradation was significantly inhibited at 800
μmol/l. These findings indicate that the inhibition of the IκB
signalling pathways by TauCl was primarily dependent on the
inhibition of IκB degradation. This finding is consistent with
previous reports showing that TauCl modifies the backbone of
IκB through amino acid oxidation of IκB, thus allowing IκB to
become resistant to degradation [39,40]. Confocal micro-
scopic examination of the NF-κB immunostaining results indi-
cated that a TauCl concentration of 800 μmol/l was required
to inhibit IκB degradation completely. Partial inhibition of IκB
degradation was seen at a TauCl concentration of 600 μmol/
l, as reflected by NF-κB immunostaining in both the cytoplasm
and the nucleus. This may indicate that signalling pathways
other than the MAPK and IκB pathways are involved in the
stimulation of MMP-1 and MMP-13. In support of this idea,
protein kinase Cδ is known to play a key role in the stimulation
of MMP-13 via crosstalk with MAPKs in basic fibroblast
growth factor stimulated human adult articular chondrocytes
[41]. At concentrations lower than 800 μmol/l, TauCl may
inhibit or block minor pathways that are involved in the upreg-
Figure 5
TauCl inhibited the migration of NF-κB into the nucleus TauCl inhibited the migration of NF-κB into the nucleus. To visualize the translocation of nuclear factor-κB (NF-κB), synovial cells (4 × 104 cells/well 
in four-well Lab-Tek chamber slides) were cultured. After serum starvation overnight, the cells were treated with taurine chloramine (TauCl) 30 min 
before stimulation with IL-1β (10 ng/ml) for 90 min. IL-1β stimulation induced the migration of NF-κB from the cytoplasm into the nucleus (second 
column), whereas NF-κB was found only in the cytoplasm of nonstimulated cells (first column). At a concentration of 800 μmol/l, TauCl completely 
inhibited the migration of NF-κB into the nucleus (fifth column). All pictures were taken at a magnification of 200×. Three independent experiments 
were performed in duplicate with cells from two patients.Arthritis Research & Therapy    Vol 9 No 4    Kim et al.
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ulation of MMP-1 and MMP-13. At a critical concentration
(600 to 800 μmol/l), IκBα degradation is completely inhibited,
thereby preventing the migration of NF-κB into the nucleus.
TauCl is less toxic than its precursor HOCl/OCl-, but cytotoxic
effects of TauCl at high concentrations have been reported. Its
toxicity appears to differ between cell types [42]. Kontny and
coworkers [43] reported that TauCl caused progressive
necrosis of RA FLSs at concentrations of 500 μmol/l or
greater. In our study, the RA FLSs used in the experiments
were not significantly affected by a TauCl concentration of
800  μmol/l for 24 hours, even though cytotoxicity was
detected in RA FLSs from some patients (Figure 6). TauCl tox-
icity appeared to vary between individual RA patients. In
addition, different cell passages might have contributed to the
variance in sensitivity to TauCl, because RA FLSs exhibit dif-
ferent characteristics according to passage [44,45]. Although
it remains uncertain whether the TauCl concentration used in
this experiment can be a physiologic concentration, TauCl may
remain at a high concentration in extracellular fluids because
the intracellular and extracellular concentrations of taurine in
mammalian tissues are 10 to 70 mmol/l and 20 to 100 μmol/
l, respectively [46].
The differential effects of TauCl on the expressions of MMP-1
and MMP-13 may also be related to other transcription factors
that are differentially involved in the activations of MMP-1 and
MMP-13. For example, Runxa2 was found to stimulate strongly
the transcriptional activation of MMP-13, but it had no effect
on MMP-1 expression in human chondrosarcoma cells [47]. In
addition, many transcriptional binding sites, such as activator
protein-1 and Ets/polymavirus enhancer 3 (OSE-2), have been
identified in the human MMP-13 proximal promoter [48-50].
An AG-rich element regulatory site was recently found in the
human MMP-13 proximal promoter [51]. This and other tran-
scription factors may contribute to the increased expression of
MMP-13 in IL-1β stimulated FLSs. The interaction of TauCl
with these as yet unidentified factors remains unknown.
Furthermore, these transcription factors may function at a
TauCl concentration that inhibits the degradation of IκB.
The degree of the inhibitory effect of TauCl was compared
with that of an NF-κB inhibitor, namely MG132. At a concen-
tration of 800 μmol/l, the inhibitory effect of TauCl on IκB deg-
radation was as potent as that of 1 μmol/l MG132. Because
MMP-13 exhibits the greatest activity toward the degradation
of type II collagen, a major component of the cartilage extracel-
lular matrix, the control of MMP-13 expression is crucial when
attempting to delay the degradation of cartilage [26]. At lower
concentrations of TauCl, inhibition of MMP-13 expression
would be a potentially effective strategy to control the destruc-
tion of joint cartilage in RA and osteoarthritis. Above all, TauCl
may be produced as a part of the homeostatic response to
infection and inflammation, thus playing a critical role in limiting
the duration and intensity of immune inflammation [52]. In sup-
Figure 6
Effect of TauCl on the viability of RA FLSs Effect of TauCl on the viability of RA FLSs. Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLSs) from two RA patients were treated with tau-
rine chloramine (TauCl) 30 min before the stimulation with IL-1β (10 ng/ml), and were incubated for 24 hours (as described in Materials and meth-
ods). Cell activity was then determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, and is expressed as the mean ± 
standard deviation of three separate experiments. Three independent experiments were performed with cells from two patients. *P < 0.05 versus 
untreated control.Available online http://arthritis-research.com/content/9/4/R80
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port of this hypothesis, synovial fluid neutrophils of RA patients
exhibit impaired generation of TauCl [53].
In summary, TauCl differentially inhibited the increased expres-
sion levels of MMP-1 and MMP-13 in IL-1β stimulated RA
FLSs. It inhibited the expression of MMP-1 primarily through
inhibition of IκB degradation, although it did not appear to
inhibit the expression of MMP-13 through inhibition of the IκB
signalling pathway.
Conclusion
Given that MMP-13, which is inhibited by TauCl, is remarkably
active against collagen type II, and that synovial fluid neu-
trophils of RA patients exhibit impaired generation of TauCl,
the involvement of TauCl in destruction of joint cartilage
should receive greater focus. This may yield insights into the
molecular mechanisms of joint destruction in RA.
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